Global Calcium is one of the leading manufacturers and exporters of
Tranexamic Acid CAS no. 1197-17-7, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.
As manufacturer of Tranexamic Acid we hereby state the following facts about the drug:
Indications for Use
Taken orally, tranexamic acid is indicated for the treatment of cyclic heavy menstrual bleeding in premenopausal females, hereditary angioedema, and other instances of significant bleeding in the context of hyperfibrinolysis.
Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
Tranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain). This inhibits plasmin formation and displaces plasminogen from the fibrin surface. It may also directly inhibit plasmin and partially inhibit fibrinogenolysis at higher concentrations.
Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market